Supernus Pharmaceuticals

SupernusPharmaceuticals is a specialty pharmaceutical company that develops and commercializes products for the treatment of central nervous system disorders, with a particular emphasis on epilepsy and attention‑deficit/hyperactivity disorder. Its marketed portfolio includes extended‑release formulations such as Trokendi XR for seizure control, Oxtellar XR for epilepsy, and Qelbree for ADHD, as well as other therapeutics like Sprix for acute pain management. The company focuses on delivering innovative drug delivery technologies that improve dosing convenience and patient adherence. Its products are primarily distributed within the United States, although it also engages in international partnerships to make certain therapies available outside the domestic market.

The firm distinguishes itself through a strong commitment to research and development in the CNS therapeutic area, leveraging proprietary formulation expertise to create extended‑release and abuse‑deterrent versions of existing molecules. Supernus has secured multiple approvals from the U.S. Food and Drug Administration, underscoring its regulatory competence and ability to bring new treatments to market. Its strategic focus on niche CNS indications allows it to compete effectively against larger pharmaceutical companies by addressing unmet needs in specialized patient populations. The organization also maintains an active pipeline of investigational candidates aimed at expanding its therapeutic offerings in neurology and psychiatry.

While the prompt does not provide explicit quantitative metrics such as revenue or employee count, publicly available sources indicate that Supernus Pharmaceuticals operates with a commercial footprint that spans the United States and includes select international distribution arrangements. The company’s headquarters are located in Rockville, Maryland, United States of America, reflecting its domestic base of operations. Structurally, Supernus Pharmaceuticals is an independent, publicly traded corporation listed on the NASDAQ stock exchange under the ticker symbol SUPN, and it is incorporated in the State of Delaware. It does not report a parent company, and its subsidiaries are primarily wholly‑owned entities that support its development, manufacturing, and commercialization activities.